Back

Comparative safety and effectiveness of standard doses of apixaban versus dabigatran, rivaroxaban, and VKAs in non-valvular atrial fibrillation patients in France: the NAXOS study

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Identifying and managing complications of atrial fibrillation Oral Anticoagulation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Nicolas Danchin

Saint Joseph Hospital, Paris (France)

5 More presentations in this session

Presentation thumbnail
Stroke severity and subsequent mortality are worse with atrial fibrillation than in patients without atrial fibrillation
Ms N. Vinding (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Resumption of anticoagulant treatment in patients with atrial fibrillation following gastrointestinal bleeding: a nationwide cohort study
Miss D. Rajan (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
ETNA-AF Europe: First 1-year follow-up snapshot analysis of more than 7,500 AF patients treated with edoxaban in routine clinical practice
Professor R. De Caterina (Pisa, IT)
Abstract Slides
Presentation thumbnail
Left atrial dimension and risk of cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis
Doctor P. Meyre (Hamilton, CA)
Abstract Slides
Presentation thumbnail
Right atrial low voltage zone as a novel predictor of sinus node dysfunction in patients with non-paroxysmal atrial fibrillation
Doctor T. Kondo (Hiroshima, JP)
Abstract Slides

Access the full session

Session thumbnail
Identifying and managing complications of atrial fibrillation

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources